

For prescribers licensed in Colorado



Pursuant to the Colo. Rev. Stat. § 12-42.5-308 (2019), GSK makes the following pricing disclosure to individuals licensed by the State of Colorado to prescribe prescription drugs. The price(s) below represent the wholesale acquisition cost (or WAC), also known as list price, for NUCALA¹ as of the date of this notice.

WAC is the listed price to wholesalers not including prompt pay, stocking or distribution allowances, or other discounts, rebates, or chargebacks. Listed price may not represent prices charged to other customers. For more information on the prices that patients pay, please check with the patient's healthcare provider.

Where available, GSK also identifies up to three (3) generic prescription drugs from the same therapeutic class as the GSK product listed. Please note that the identification of any generic product in the table below does not imply that that product is preferred, available commercially, interchangeable with any other product, nor is it intended to be a claim regarding the efficacy or safety of that product.

Prices are subject to change without notice. This notice is not a solicitation and does not constitute an offer to sell any GSK product.

WAC for NUCALA (mepolizumab) for injection, for subcutaneous use as of January 2026

<u>GSK Product Name w/ Strength</u>	<u>NDC or UPC</u>	<u>Pkg Size</u>	<u>WAC (Pkg)</u>	<u>Generic</u>	<u>Generic</u>	<u>Generic</u>
NUCALA INJ 100MG/ML	00173-0892-01	1 ML/1 autoinjector	\$3,990.98	N/A	N/A	N/A
NUCALA INJ 100MG/ML	00173-0892-42	1 ML/1 syringe	\$3,990.98	N/A	N/A	N/A
NUCALA 40MG/0.4ML	00173-0904-42	0.4 ML/1 syringe	\$1,596.41	N/A	N/A	N/A
NUCALA INJ 100MG	00173-0881-01	1 EA/ 1 vial	\$3,674.88	N/A	N/A	N/A

Prices appearing on this form were obtained from GSK data on file as of January 2026.

To access the full Prescribing Information for the GSK product, please visit us at <https://gsksource.com/pharma/content/gsk/source/us/en/brands.html?type=Prescription>

¹ Trademarks are owned by or licensed to the GSK group of companies

For prescribers licensed in Connecticut



Pursuant to Connecticut Public Act No. 23-171 (2023), GSK makes the following pricing disclosure to a practitioner or pharmacist licensed by the State of Connecticut to prescribe prescription drugs. The price(s) below represent the wholesale acquisition cost (or WAC), also known as the list price, for NUCALA¹ as of the date of this notice.

WAC is the listed price to wholesalers not including prompt pay, stocking or distribution allowances, or other discounts, rebates, or chargebacks. Listed price may not represent prices charged to other customers. For more information on the prices that patients pay, please check with the patient's healthcare provider.

As required by Act No. 23-171, where available, GSK also provides information on the variation efficacy of the prescription drug to the prescribing practitioner or pharmacist based on the dose and quantity of that drug to marketed to different racial and ethnic groups.

Prices are subject to change without notice. This notice is not a solicitation and does not constitute an offer to sell any GSK product.

WAC for NUCALA (mepolizumab) for injection, for subcutaneous use as of January 2026

<u>GSK Product Name w/ Strength</u>	<u>NDC or UPC</u>	<u>Pkg Size</u>	<u>WAC (Pkg)</u>	<u>Variation Efficacy Information (If Available)</u>
NUCALA INJ 100MG/ML	00173-0892-01	1 ML/1 autoinjector	\$3,990.98	N/A
NUCALA INJ 100MG/ML	00173-0892-42	1 ML/1 syringe	\$3,990.98	N/A
NUCALA 40MG/0.4ML	00173-0904-42	0.4 ML/1 syringe	\$1,596.41	N/A
NUCALA INJ 100MG	00173-0881-01	1 EA/ 1 vial	\$3,674.88	N/A

Prices appearing on this form were obtained from GSK data on file as of January 2026.

To access the full Prescribing Information for the GSK product, please visit us at <https://gsksource.com/pharma/content/gsk/source/us/en/brands.html?type=Prescription>

¹ Trademarks are owned by or licensed to the GSK group of companies